Helix in peptide purchase deal with Peptisyntha

Washington, USA-based Helix BioMedix,a developer of bioactive peptides, today announced that it has entered into a peptide purchase agreement with Peptisyntha, a US peptide manufacturer.

The agreement includes a commitment by Helix to purchase peptides over an 18-month period for total consideration of $234,000. In addition, Helix recently completed a smaller purchase of peptides from the same supplier for $64,000.

"These purchases represent the largest peptide purchase commitment in Helix' history and reflect our expectation that our marketing partners will sell increased quantities of peptide-based products over the next eighteen months," commented Stephen Beatty, the firm's chief executive.